UT
UTI Healthcare Fund Direct Growth
Latest NAV
+16.65% 1Y
Sign In to Add to Portfolio
Benchmark: BSE Healthcare TRI
Expense ratio
1.26%
AUM
₹1,444 Cr
Min SIP
₹500
Min lump sum
₹5,000
1Y
+16.65%
3Y (ann.)
+22.55%
5Y (ann.)
+15.31%
Launched
Jan 2013
Where the NAV sits & how risky it is
₹378.65
52-week range
at 82%
₹378.65
Low 29 Jan 2026₹304.48
High 23 Sep 2026₹394.99
Risk level
Very High
Low
Very high
NAV history
02 Jan 2013
Since inception
01 Oct 2026
Returns by period
1W
-3.57%
1M
-3.23%
3M
+2.34%
6M
+22.59%
1Y
+16.65%
3Y
+22.55%
5Y
+15.31%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹500
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 94.45%
Cash & other 5.55%
Sector split
Country split
Top 5 hold 26.2%
Top 10 hold 42.1%
43 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.87%
|
+4.09% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.87%
|
+5.64% |
| 3 | Ajanta Pharma
INE031B01049 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.70%
|
+8.97% |
| 4 | Gland Pharma
INE068V01023 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.98%
|
+32.90% |
| 5 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.80%
|
+7.33% |
| 6 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
3.56%
|
+21.18% |
| 7 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.11%
|
-0.23% |
| 8 | Caplin Point Laboratories
INE475E01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.08%
|
+22.91% |
| 9 | Alkem Laboratories
INE540L01014 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.07%
|
-1.96% |
| 10 | Fortis Healthcare
INE061F01013 |
Healthcare Medical Care Facilities |
India |
3.05%
|
+11.96% |
About this scheme
The primary objective of the scheme is to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector. However, there can be no assurance or guarantee that the investment objective of the scheme would be achieved.
Fund manager(s): Kamal Gada
Exit load: Exit load of 1% if redeemed within 30 days.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
01 Jan 2013
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 104.9 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 16.7 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 13.9 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 13.9 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 12.6 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 12.5 pts ahead of this fund